Ropivacaine - Jiangsu HengRui Medicine
Alternative Names: HR-18034; Ropivacaine liposome - Jiangsu HengRui MedicineLatest Information Update: 25 Jul 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 19 Jul 2024 Shanghai Hengrui Pharmaceutical plans a phase II trial for Postoperative Pain in August 2024 (Injection) (NCT06509958)
- 30 Oct 2023 Jiangsu Hengrui Medicine completes a phase-III trial in Postoperative pain in China (NCT05769855)
- 15 Mar 2023 Shanghai Hengrui Pharmaceutical plans a phase III trial for Postoperative pain in March 2023 (Unspecified) (NCT05769855)